Botulinum neurotoxin (BoNT) is the most potent natural toxin known. Of the seven BoNT 23 serotypes (A to G), types A, B, E, and F cause human botulism. Treatment of human botulism 24 requires the development of effective toxin-neutralizing antibodies without side effects such as 25 serum sickness and anaphylaxis. In this study, we generated fully human monoclonal antibodies 26 (HuMAbs) against serotype B BoNT (BoNT/B1) using a murine-human chimera fusion partner 27 cell line named SPYMEG. Of these HuMAbs, M2, which specifically binds to the light chain of 28
INTRODUCTION 54
Botulinum neurotoxins (BoNTs) produced by the anaerobic bacterium Clostridium botulinum 55 and related species cause botulism, a neuroparalytic disease with high mortality (1,2). BoNTs 56 have been classified as category A agents by the Centers of Disease Control and Prevention 57 (CDC) and are listed among the six agents at highest risk of being used as bioweapons (3). Seven 58 serotypes, designated A to G, have been identified, and four of these, namely A, B, E, and F, 59 cause human botulism 2 . It was recently reported that BoNT/H is produced by the novel C. 60 botulinum strain IBCA10-7060, which also produces BoNT/B (4,5), and subsequent studies have 61 suggested that BoNT/H is a hybrid-toxin of BoNT/A1 and BoNT/F5 (6-8). 62
Each BoNT is synthesized as a single polypeptide chain (150 kDa) that is proteolytically 63 activated by cleavage into a light chain (L chain, 50 kDa) and a heavy chain (H chain, 100 kDa), 64 9 one hybridoma clone, designated M7, was produced IgA. Furthermore, an IgG subclass assay 118 revealed that M2, M4, and S1 were each comprised of an IgG1 H chain and L (lambda) chain 119 (Table 2) . 120 121 Binding specificity of HuMAbs 122
We selected three IgG1 HuMAbs, namely M2, M4, and S1, and analyzed the binding activity 123 of these HuMAbs against BoNT/A1 and BoNT/B1 by ELISA. All three HuMAbs bound to 124
BoNT/B1, whereas none bound to BoNT/A1 (Fig. 1) . We next performed ELISA using 125 recombinant proteins to determine whether the HuMAbs recognized the L and H chains (H N , H C ) 126 of BoNT/B1. M2 and S1 bound to the L chain of BoNT/B1, while M4 bound to the H C . All three 127
HuMAbs did not bind to H N ( Fig. 2A ). To further investigate if the epitopes recognized by 128 HuMAbs overlapped, we performed competitive ELISA. Non-labeled M2 and S1 were equally 129 effective at inhibiting the binding of HRP-labeled M2 to BoNT/B1 and that of binding of HRP-130 labeled S1 to BoNT/B1, suggesting that M2 and S1 recognized overlapping epitopes. By 131 contrast, binding of HRP-labeled M4 was not inhibited by non-labeled M2 and S1, indicating 132 that M4 recognized a different epitope than M2 and S1 ( Fig. 2B ). 133 10 134
Neutralization activity of HuMAbs 135
The neutralization activity of HuMAbs against BoNT/B1 was determined by mouse bioassay. 136 A dose of 10 mouse intraperitoneal (i.p.) lethal dose 50% (LD 50 ) of BoNT/B1 was incubated 137 with 100 µg of HuMAb for 1 h prior to i.p. injection into mice. Control mice treated with PBS 138 died within 12 h. By contrast, mice treated with M4 were partially protected, as evidenced by an 139 increased time-to-death compared with control mice. Furthermore, complete protection was 140 observed in mice treated with M2 ( Fig. 3A) . Because the S1-producing hybridoma had low 141 productivity, we could not obtain a sufficient quantity of S1 to test its neutralization activity in 142 the mouse bioassay. 143
It is known that a combination of monoclonal antibodies shows a synergistic effect 144 neutralizing BoNT (23-26). Thus, we next tested for potential synergy of a combination of 145 HuMAbs. A dose of 10 i.p. LD 50 of BoNT/B1 was incubated with two combinations of HuMAbs 146 (5.0 µg each) and injected into mice. The combination of M2 and S1 showed a very weak 147 synergistic effect, and the combination of M4 and S1 showed partial protection. By contrast, all 148 of the mice that received the combination of M2 and M4 (M2+M4, 5.0 µg or 0.5 µg each) 149 11 survived and had no symptoms ( Fig. 3B, 3C ), indicating that this combination acted highly 150 synergistically in neutralizing BoNT/B1. Based on these results, we used M2 and M4 in 151 subsequent experiments. We obtained the sequences of the variable domains of the H and L 152 chains of these antibodies using reverse transcription polymerase chain reaction (RT-PCR) with 153 consensus primers ( Fig. 4) . 154
BoNTs are always produced along with one or more neurotoxin-associated proteins that non-155 covalently associate with the BoNT to form progenitor toxin complexes (PTCs). Several studies have confirmed a synergistic effect when two or more antibodies are combined 201 (23-26). The combination of the HuMAbs M2 and M4, which recognize non-overlapping 202 epitopes, was able to completely neutralize BoNT/B1 with a potency greater than 10,000 i.p. 203 LD 50 /mg of antibodies ( Fig. 3B , C). This potency is over 12.5 times greater than that of 204 BabyBIG (18) (800 LD 50 /mg of antibodies), an orphan drug that consists of human-derived anti-205 botulinum toxin antibodies. By contrast, the combination of M2 and S1, which recognize 206 overlapping epitopes, showed no synergistic effect. This result suggests that the recognition of 207 non-overlapping epitopes is critical for a synergistic effect in BoNT neutralization. Meanwhile, 208 the combination of M4 and S1 showed only partial protection even though M4 and S1 recognize 209 non-overlapping epitopes. The antigen binding affinity of S1 might be lower than that of M2, or 210 the amino acid sequence of BoNT/B1 recognized by S1 might be slightly different from that of 211 BoNT/B1 (28,29,44,45). However, M2 and M4 exhibited strong binding and high neutralization 244 activity against BoNT/B2 and BoNT/B6 as well as against BoNT/B1 (Fig. 6) . These data 245
indicate that M2 and M4 may be effective for the treatment and prevention of botulism caused by 246 several subtypes of BoNT/B. 247
In conclusion, we developed anti-BoNT/B antibody-producing hybridomas using the 248 SPYMEG cell line, and obtained two neutralizing antibodies, M2 and M4. This method can be 249 applied to other botulinum serotypes, and it will be possible to maintain a stable supply of 250 HuMAbs using these hybridomas. Because of their human origin, M2 and M4 are safe for the 251 treatment of human botulism, including infant botulism. Furthermore, we found that the 252 combination of M2 and M4 had potent neutralization activity, greater than that of BabyBIG, 253 against BoNT/B1, and neutralized two other subtypes. Additionally, M2+M4 showed therapeutic 254 and preventive effects against botulism in mouse models. These data indicate that the fully 255 human monoclonal antibodies, M2 and M4, are promising candidates for the development of Competition ELISA 325 M2, M4, and S1 were labeled with HRP using Perioxidase Labeling Kits (Dojindo Molecular  326 Technologies, Kumamoto, Japan). The optimal dilutions of HRP-labeled HuMAbs were 327 determined by ELISA based on an Abs 405 value around 2.0. Non-labeled HuMAb (2.5 µg/ml) 328 was added to plates coated with BoNT/B1 and incubated for 2 h at 37 °C. After washing, HRP-329 labeled M2 (1:5000), M4 (1:5000), or S1 (1:1000) was added and incubated for 2 h at 37 °C. 330
Plates were washed again and incubated with substrate solution (ABTS) for 20 min at 37 °C, and 331 absorbance values at Abs 405 were measured. 332 333
Sequencing of HuMAb variable region gene segments 334
Total RNA was extracted from the hybridomas using an RNeasy Mini Kit (Qiagen, Hilden, 335
Germany), and cDNA was synthesized by RT-PCR using a SuperScript® VILO TM cDNA 336 Synthesis Kit (Invitrogen). The coding regions of the H and L chains of M2 and M4 were 337 amplified by PCR using KOD-Plus-Neo (TOYOBO, Osaka, Japan), with the following primers: The neutralization activity of HuMAbs was tested by mouse bioassay. Female ddY mice were 347 purchased from SLC (Shizuoka, Japan) and were used at 4 weeks of age. One or more HuMAbs 348 was incubated with BoNT/B1, BoNT/B2, or BoNT/B6 at room temperature for 1 h prior to i.p. 349 injection (in a total volume of 500 µl) into mice. In control mice, BoNT was incubated with PBS 350 instead of HuMAbs. In the botulism treatment (post-exposure) model, the B1 subtype progenitor 351 toxin (L-PTC, 10 ng in a volume of 300 µl) was orally administered and M2+M4 was 352 subsequently administered at 12, 24, and 36 h after oral administration of L-PTC by i.p. 353 injection. In the botulism prevention (pre-exposure) model, M2+M4 was administered by i.p. 354 injection and mice were then challenged at 1, 3, 5, or 7 days later with 10 i.p. LD 50 HuMAbs (2.5 µg/ml) were added to plates coated with BoNT/B1, and then HRP-labeled M2 597
(1:5000), M4 (1:5000), or S1 (1:1000) was added. Bound HRP-labeled HuMAbs were 598
